What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
Arcturus Therapeutics (ARCT) reported Q3 revenue of $18.3M, up from $17.2M YoY, with a net loss of $0.26 per share. The company plans to begin Phase II trials for ARCT-2601 in Q1 2027 and submit an IND application for a PKU treatment in H2 2027. ARCT-810 showed positive Phase II data, and LUNAR 2.0 tech demonstrated a 38-fold potency improvement in non-human tests. Cash reserves were $184.8M as of Q3 2026.
How this was made
The 30-second read
Why it matters
Earnings and trial updates provide fresh catalysts that could move the stock in the short term.
Market read
The announcement is relevant for biotech investors tracking RNA therapeutics and for traders seeking short‑term moves on earnings beats.
What to watch
Potential regulatory delays for IND filing and competition from other RNA platforms.
Background
Arcturus Therapeutics (NASDAQ:ARCT) reported Q3 results and outlined upcoming Phase II studies for its liver disorder program.
Ticker impact
Q3 earnings disclosed a narrowed loss, $18.3M revenue and new Phase II plans for ARCT-2601, plus trial results for ARCT-810.
likely modest upside as market prices in improved financials and Phase II initiation.
First report of Q3 numbers and new Phase II dosing schedule provides fresh material for traders.
Market effects
Positive data may boost sentiment in the RNA therapeutics sector.
Limited to US biotech investors; no broader regional effect.
Modest, confined to biotech and specialty pharma investors.
Counterpoint
Loss remains sizable and cash burn high; price could face pressure if guidance is not raised.
Key entities
- companyArcturus Therapeutics
Biotech firm developing RNA medicines.
